

CEFIDEROCOL POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION

(CEFIDEROCOLI PULVIS PRO CONCENTRATO PRO SOLUTIONE PRO INFUSIONE)

Draft proposal for inclusion in The International Pharmacopoeia

(09 December 2025)

DRAFT FOR COMMENTS

Please submit your comments through the online platform, PleaseReview™

https://who.pleasereview.net/Main/Default.aspx?action=loaddocument&reviewid=371

If not registered or included in our mailing list, kindly submit your request with your full name, email address and organization/affiliation to nsp@who.int.

For any technical questions, you may contact **Dr Herbert Schmidt**, Technical Officer, Norms and Standards for Pharmaceuticals, Technical Standards and Specifications (schmidth@who.int), with a copy to Ms Sinéad Jones (jonessi@who.int, nsp@who.int).

Comments should be submitted through the online platform on or by **09 February 2026**. Please note that only comments received by this deadline will be considered for the preparation of this document.

Our working documents are sent out electronically and uploaded into PleaseReviewTM. The working documents are also placed on the WHO Medicines website (https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/pharmaceuticals/working-documents-public-consultation) under the "Working documents in public consultation".

© World Health Organization 2025

All rights reserved.

This is a draft. The content of this document is not final, and the text may be subject to revisions before publication. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization.

Please send any request for permission to: Norms and Standards for Pharmaceuticals, Technical Standards and Specifications, Department of Health Products Policy and Standards, World Health Organization, CH-1211 Geneva 27, Switzerland, email: nsp@who.int.

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this draft.

However, the printed material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This draft does not necessarily represent the decisions or the stated policy of the World Health Organization.

37 38

39

40 41

42 43 44

CEFIDEROCOL POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION

(CEFIDEROCOLI PULVIS PRO CONCENTRATO PRO SOLUTIONE **PRO INFUSIONE**)

SCHEDULE FOR THE ADOPTION PROCESS OF DOCUMENT QAS/24.968

Description	Date
Drafting of the monograph by the Secretariat based on information received from manufacturers and found in the public domain.	July 2024
Draft monograph sent out for public consultation.	July to August 2025
Presentation to the 58 th meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations.	October 2025
Draft monograph sent out for public consultation	December 2025 to February 2026
Further follow-up action as required.	

- [Note from the Secretariat. The monograph on Cefiderocol powder for concentrate 46
- for solution for infusion is proposed for inclusion in The International Pharmacopoeia. 47
- Being one of the first public standards, the monographs on Cefiderocol sulfate tosilate 48
- and Cefiderocol powder for concentrate for solution for infusion are expected to play 49
- an important role in ensuring access to safe, effective and quality-assured essential 50
- medicines. Manufacturers, regulatory authorities, procurement agencies and other 51
- stakeholders are therefore invited to provide their feedback on the proposed 52
- specifications and analytical procedures. 53
- The draft monograph is based on information and samples received from a 54
- manufacturer, found in the public domain and on laboratory investigations. 55

Draft monographs are subject to change.]



CEFIDEROCOL POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION

- 59 **Category.** Antibacterial (reserve group antibiotic).
- 60 Storage. Cefiderocol powder for concentrate for solution for infusion should be kept in
- a hermetically closed container and protected from light.
- 62 Additional information. Strength in the current WHO Model List of Essential
- 63 Medicines (EML): Powder for injection: 1 g of cefiderocol in vial.

64 Requirements

57

58

- 65 Cefiderocol powder for concentrate for solution for infusion complies with the
- 66 monograph for *Parenteral preparations*.
- **Definition.** Cefiderocol powder for concentrate for solution for infusion is a sterile
- product consisting of a mixture of Cefiderocol sulfate tosilate and excipients. It is
- supplied in sealed vials and contains not less than 90.0% and not more than 110.0% of
- 70 the labelled amount of cefiderocol ($C_{30}H_{34}ClN_7O_{10}S_2$) per vial.

Identity tests

- Either test A, or tests B and C, may be applied.
- A. Carry out the test as described under 1.14.1 Chromatography, High-performance
- 74 liquid chromatography, using the conditions given under "Assay" but using, as
- 75 the detector, a diode array detector to record the UV spectra of the peaks due to
- cefiderocol and 4-toluenesulfonic acid in each chromatogram in the range of 210
- nm to 350 nm and injecting 10 µL of solutions (2) and (3). The retention times
- and the UV spectra of the peaks due to cefiderocol and 4-toluenesulfonic acid in
- 79 the chromatogram obtained with solution (2) correspond to the retention times
- and the UV spectra of the peaks due to cefiderocol and 4-toluenesulfonic acid in

- the chromatogram obtained with solution (3).
- 82 B. Carry out the test as described under 1.14.1 Chromatography, High-performance
- liquid chromatography, using the conditions and solutions given under "Assay"
- but injecting 10 μL of solutions (2) and (3).
- The retention times of the peaks due to cefiderocol and 4-toluenesulfonic acid in
- the chromatogram obtained with solution (2) correspond to the retention times of
- the peaks due to cefiderocol and 4-toluenesulfonic acid in the chromatogram
- obtained with solution (3).
- 89 C. Carry out the test as described under 1.14.1 Chromatography, Thin-layer
- chromatography, using silica gel R7 as the coating substance and a mixture of 1
- volume of methanol R and 2 volumes of water R as the mobile phase.
- Apply separately to the plate 10 μL of each of the following four solutions in
- methanol R. For solution (A), shake a quantity of the powder, nominally
- equivalent to 10 mg of cefiderocol, for 5 minutes with 10 mL of methanol R,
- 95 filter and use the clear filtrate. For solution (B), shake a quantity of the powder,
- nominally equivalent to 200 mg of cefiderocol for 5 minutes with 10 mL of
- 97 methanol R, filter and use the clear filtrate. For solution (C), use a solution
- containing 1.35 mg of cefiderocol sulfate tosilate RS per mL. For solution (D),
- use a solution containing 6.1 mg of 4-toluenesulfonic acid R per mL. After
- removing the plate from the chromatographic chamber, allow it to dry in air, and
- examine the chromatogram in ultraviolet light (254 nm).
- The principal spot obtained with solution (A) corresponds in position,
- appearance and intensity with the spot due to cefiderocol in the chromatogram
- obtained with solution (C). The spot with an R_F value of about 0.83 obtained
- with solution (B) corresponds in position, appearance and intensity with the spot
- due to 4-toluenesulfonic acid in the chromatogram obtained with solution (D).

- pH value. Carry out as described under 1.13 Determination of pH. Dissolve the contents of 1 vial of the powder for concentrate for solution for infusion in 10 mL of carbon-dioxide water R. pH of the obtained solution, is 5.0 to 6.0.
- Clarity and colour of solution. Dissolve the contents of 1 vial of the powder for concentrate for solution for infusion in 10 mL of water R. This solution is clear and not more intensely coloured than reference solution Y5, when compared as described under 1.11.2 Degree of coloration of liquids, Method I.
- Related substances. Carry out the test as described under 1.14.1 Chromatography,
 High-performance liquid chromatography, using a stainless-steel column (2.1 mm
 x 15 cm) packed with particles of silica gel, the surface of which has been modified
 with chemically-bonded octadecylsilyl groups (1.6 μm).
- Prepare a 0.2% trifluoroacetic acid solution by diluting 2.0 mL of trifluoroacetic acid R to 1000.0 mL with water R.
- 120 Use the following conditions for gradient elution:
- mobile phase A: a mixture of 0.2% trifluoroacetic acid solution and
 acetonitrile R (97:3 V/V);
- mobile phase B: acetonitrile R.

Time (minutes)	Mobile phase A (% V/V)	Mobile phase B (% V/V)	Comments
0-0.5	100	0	Isocratic
0.5-4.0	100 to 89	0 to 11	Linear gradient
4.0–9.0	89	11	Isocratic
9.0–30.0	89 to 62	11 to 38	Linear gradient
30.0–31.0	62 to 100	38 to 0	Return to initial composition
31.0–40.0	100	0	Re-equilibration

¹ A CORTECS UPLC T3 or a CORTECS UPLC C18 column have been found suitable.

- Operate with a flow rate of 0.3 mL per minute. Maintain the column temperature
- at 35 °C and the autosampler at 5 °C. As a detector, use an ultraviolet
- spectrophotometer set at a wavelength of 261 nm.
- 127 Prepare the following solutions:
- Sodium dihydrogen phosphate solution (0.05 mol/L): dissolve 7.80 g of
- sodium dihydrogen phosphate dihydrate R in water R and dilute to 1000 mL
- with the same solvent.
- Disodium hydrogen phosphate solution (0.05 mol/L): dissolve 7.098 g of
- anhydrous disodium hydrogen phosphate R in water R and dilute to 1000
- mL with the same solvent.
- Phosphate buffer solution (5 mmol/L): prepare a mixture of water R,
- sodium dihydrogen phosphate solution (0.05 mol/L), and disodium
- hydrogen phosphate solution (0.05 mol/L) (18:1:1 V/V/V).
- Use as a diluent a mixture of phosphate buffer solution (5 mmol/L) and
- acetonitrile R (9:1 V/V).
- For solution (1), use solution (1) as described under "Assay".
- For solution (2), dilute 1.0 mL of solution (1) to 100.0 mL with diluent.
- For solution (3), dilute 5.0 mL of solution (2) to 100.0 mL with the diluent.
- For solution (4), transfer 32 mg of cefiderocol sulfate tosilate RS into a 20 mL
- volumetric flask, dissolve in diluent and dilute to volume with the same diluent.
- Heat the obtained solution at 50 °C for 20 minutes and cool to room temperature.
- Inject 2 μ L each of solutions (1), (2), (3) and (4).
- Use the chromatogram obtained with solution (4) to identify the peaks due to 4-
- toluenesulonic acid, and the impurities A, B, C, E and G.

- In the chromatogram obtained with solution (1), the impurities are eluted, if present, at the following relative retentions with reference to cefiderocol (retention time about 10 minutes): 4-toluenesulfonic acid about 0.40; impurity A about 0.45; impurity B about
- 0.61; impurity C about 0.76; impurity F about 0.83, impurity D about 1.23, impurity E
- about 1.28 and impurity G about 1.83.
- The test is not valid unless, in this chromatogram obtained with solution (4), the
- resolution between the peaks due to 4-toluenesulfonic acid and impurity A is at least
- 1.5. Also, the test is not valid unless, in the chromatogram obtained with solution (3),
- the peak due to cefiderocol is obtained with a signal-to-noise ratio of at least 20.In the
- chromatogram obtained with solution (1):
- the area of any peak corresponding to impurity A, when multiplied with a correction factor of 2.4, is not greater than 1.4 times the area of the peak due to cefiderocol in the chromatogram obtained with solution (2) (1.4 %);
- the area of any peak corresponding to impurity G, when multiplied with a correction factor of 1.6, is not greater than 0.7 times the area of the peak due to cefiderocol in the chromatogram obtained with solution (2) (0.7 %);
- the area of any peak corresponding to impurity E is not greater than 0.15 times the area of the peak due to cefiderocol in the chromatogram obtained with solution (2) (0.15 %);
- the area of any peak corresponding to impurity B, when multiplied with a correction factor of 0.72, is not greater than 0.1 times the area of the peak due to cefiderocol in the chromatogram obtained with solution (2) (0.10 %);
- the area of any other impurity peak is not greater than 0.1 times the area of the peak due to cefiderocol in the chromatogram obtained with solution (2) (0.10 %).
- The sum of the areas of all impurity peaks, including the corrected areas of any peaks corresponding to impurities A, B and G, is not greater than 2.6 times the area of the peak due to cefiderocol in the chromatogram obtained

with solution (2) (2.6 %). Disregard all peaks with an area of less than the 176 area of the peak due to cefiderocol in the chromatogram obtained with 177 solution (3) (0.05 %) and any peak due to 4-toluenesulfonic acid. 178 **Assay.** Carry out the test as described under 1.14.1 Chromatography, High-179 performance liquid chromatography, using a stainless-steel column (4.6 mm x 10 180 cm) packed with particles of silica gel, the surface of which has been modified with 181 chemically-bonded octadecylsilyl groups (3 µm).² 182 Prepare a 0.1% trifluoroacetic acid solution by diluting 1.0 mL of trifluoroacetic 183 acid R to 1000.0 mL with water R. 184 As the mobile phase, use a mixture of 0.1% trifluoroacetic acid solution and 185 acetonitrile (86:14 V/V). 186 Operate with a flow rate of 1.0 mL per minute. Maintain the column temperature 187 at 35 °C and the autosampler at 5 °C. Use an ultraviolet spectrophotometer set at a 188 wavelength of 261 nm. 189 Prepare the following solutions: 190 Sodium dihydrogen phosphate solution (0.05 mol/L): dissolve 7.80 g of 191 sodium dihydrogen phosphate dihydrate R in water R and dilute to 1000 mL 192 with the same solvent. 193 Disodium hydrogen phosphate solution (0.05 mol/L): dissolve 7.098 g of 194 anhydrous disodium hydrogen phosphate R in water R and dilute to 1000 195 mL with the same solvent. 196 Phosphate buffer solution (5 mmol/L): prepare a mixture of water R, 197 sodium dihydrogen phosphate solution (0.05 mol/L), and disodium 198 hydrogen phosphate solution (0.05 mol/L) (18:1:1 V/V/V). 199

² Unison UK-C18 column has been found suitable.

Use as a diluent a mixture of phosphate buffer solution (5 mmol/L) and 200 acetonitrile R (9:1 V/V). 201 For solution (1), gently remove the stoppers from 5 vials and retain the stoppers. 202 Add 10 mL of diluent to each vial and re-insert the stoppers. Swirl the vial 203 contents gently and then mix well by repeated inversions until the contents of the 204 vials are fully dissolved. Transfer the solutions into a single 500 mL volumetric 205 flask. Add again 10 mL of diluent to each vial, re-insert the stoppers, mix, and 206 transfer the rinses also to the volumetric flask. Dilute to volume with diluent. 207 Dilute 5.0 mL of this solution to 50.0 mL with the diluent. 208 For solution (2), dilute 5.0 mL of solution (1) to 50.0 mL with the diluent. 209 For solution (3), transfer 68.0 mg of cefiderocol sulfate tosilate RS into a 50 mL 210 volumetric flask, dissolve in diluent and dilute to volume with the same diluent. 211 Dilute 5.0 mL to 50.0 mL with the diluent. 212 Inject 10 µL each of solutions (2) and (3) and record the chromatograms for 20 213 minutes. In the chromatograms obtained, the substances are eluted in the order: 4-214 toluenesulfonic acid, cefiderocol. 215 Measure the areas of the peaks corresponding to cefiderocol obtained in the 216 chromatograms of solutions (2) and (3) and calculate the percentage content of 217 cefiderocol (C₃₀H₃₄ClN₇O₁₀S₂) per vial using the declared content of cefiderocol 218 (C₃₀H₃₄ClN₇O₁₀S₂) in cefiderocol sulfate tosilate RS. Each mg of C₃₀H₃₄ClN₇O₁₀S₂ 219 corresponds to 1.349 mg of $3C_{30}H_{34}ClN_7O_{10}S_2 \cdot 4C_7H_8O_3S \cdot H_2SO_4$. 220 **Bacterial endotoxins.** If intended for use in the manufacture of a parenteral dosage 221 form without a further appropriate procedure for the removal of bacterial endotoxins, 222

carry out the test as described under 3.4 Test for bacterial endotoxins; contains not

more than 0.101 IU of endotoxin per mg of the test substance.

223

226	Impurities
227	The impurities limited by the requirements of this monograph include those listed in
228	the monograph on Cefiderocol sulfate tosilate.
229	
230	Reference substances to be established.
231	Cefiderocol sulfate tosilate RS
232	New International Chemical Reference Substance to be established [With]
233	a declared content of cefiderocol].
234	Reagents to be revised.
235	4-Toluenesulfonic acid R
236	4-Methylbenzenesulfonic acid, C ₇ H ₈ O ₃ S, H ₂ O.
237	Content: minimum 87.0 % of C ₇ H ₈ O ₃ S.
238 239	<i>Description</i> : White or almost white, crystalline powder or crystals, freely soluble in water, soluble in Ethanol (~750 g/L) TS.
240	
241	***
242	